Selux Diagnostics, Inc. news

Selux Diagnostics Announces Additional $50 Million in Series C Funding

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation P

Feb. 28, yyyy

Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer

Nov. 16, yyyy

Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform

Oct. 19, yyyy

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation `Phenotyping` (NGP) Platform for Positive Blood Culture and Sterile Body Fluid samples

Sep. 28, yyyy

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples

Sep. 28, yyyy

Selux Diagnostics Receives $9.6 Million in Additional Funding, Speeding Development of Breakthrough Rapid AST Platform

Selux Diagnostics, Inc.

Apr. 27, yyyy

ECCMID 2020 Alert: Selux Diagnostics Hosting Integrated Symposium at 30th European Congress of Clinical Microbiology & Infectious Diseases

Selux Diagnostics, Inc.

Feb. 18, yyyy

Selux Diagnostics Announces Selection of Three Abstracts for Poster Sessions at ASM Microbe 2019 Conference

Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat multidrug resistant organism infections and combat antibiotic resistance, today announced the selection of three Selux-crafted abstracts for poster sessions at the upcoming American Society for Microbiology, ASM Microbe 2019 scientific meet

Jun. 10, yyyy